| pubmed-article:6207950 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6207950 | lifeskim:mentions | umls-concept:C0031330 | lld:lifeskim |
| pubmed-article:6207950 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
| pubmed-article:6207950 | lifeskim:mentions | umls-concept:C0007586 | lld:lifeskim |
| pubmed-article:6207950 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6207950 | lifeskim:mentions | umls-concept:C0049065 | lld:lifeskim |
| pubmed-article:6207950 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6207950 | pubmed:dateCreated | 1984-11-28 | lld:pubmed |
| pubmed-article:6207950 | pubmed:abstractText | The cytotoxic action of 5-aza-2'-deoxycytidine (5-AZA-CdR) in synchronized cells and logarithmic- and plateau-phase cultures of EMT6 murine tumor cells was investigated. 5-AZA-CdR produced a greater cell kill of S phase cells than of cells in G1 phase. Cells in the logarithmic phase of growth were more sensitive to the cytotoxic effects of 5-AZA-CdR than cells in the plateau phase of growth. These results indicate that 5-AZA-CdR produces a preferential kill of cells in the S phase of the cell cycle. 5-AZA-CdR did not block the cell cycle progression of cells into S phase. The survival curve of EMT6 cells exposed to 5-AZA-CdR suggests that the cytotoxic action of this analogue is not self-limiting. The mutagenic activity of 5-AZA-CdR was investigated using induction of 6-thioguanine resistance in Chinese hamster ovary cells. 5-AZA-CdR was not a detectable mutagen in this assay system. | lld:pubmed |
| pubmed-article:6207950 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6207950 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6207950 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6207950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6207950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6207950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6207950 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6207950 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:6207950 | pubmed:author | pubmed-author:MomparlerR... | lld:pubmed |
| pubmed-article:6207950 | pubmed:author | pubmed-author:RivardG EGE | lld:pubmed |
| pubmed-article:6207950 | pubmed:author | pubmed-author:SamsonJJ | lld:pubmed |
| pubmed-article:6207950 | pubmed:author | pubmed-author:MomparlerL... | lld:pubmed |
| pubmed-article:6207950 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6207950 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:6207950 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6207950 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6207950 | pubmed:pagination | 191-4 | lld:pubmed |
| pubmed-article:6207950 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:meshHeading | pubmed-meshheading:6207950-... | lld:pubmed |
| pubmed-article:6207950 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6207950 | pubmed:articleTitle | Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. | lld:pubmed |
| pubmed-article:6207950 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6207950 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6207950 | lld:pubmed |
